Study summary
Primary Sclerosing Cholangitis (PSC) is an incurable autoimmune disease affecting the bile ducts and liver. Many PSC patients also have inflammatory bowel disease (IBD). This combination increases the risk of bile duct, gallbladder, liver, or bowel cancer. While yearly colonoscopies are standard, there are no effective screening tools for these other cancers. This leads to late diagnoses and often fatal outcomes.
This study aims to investigate whether daily low-dose aspirin can reduce liver disease complications, the need for a liver transplant and premature death due to PSC.
968 volunteers with PSC and IBD will participate. Two-thirds will receive daily low-dose aspirin, while one-third will receive a placebo. Neither participants nor researchers will know who receives which treatment. Regular monitoring will involve scans, blood tests, urine tests, and quality-of-life questionnaires.